James et al1 report the results of the DAPA-MI (DAPAagliflozin in patients without diabetes mellitus with acute Myocardial Infarction) trial, which studied the efficacy and safety of early initiation of dapagliflozin, a sodium glucose cotransporter-2 (SGLT2) inhibitor, in patients with acute myocardial infarction (MI) without type 2 diabetes (T2D) or heart failure (HF). The trial was conducted within the SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) and NICOR (National Institute for Cardiovascular Outcomes Research) registries, leveraging where possible routinely collected health data to augment screening, baseline characteristic ascertainment, and clinical follow-up.